Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA. .
Clinical Cancer Research (Impact Factor: 8.72). 04/2010; 16(8):2443-9. DOI: 10.1158/1078-0432.CCR-09-3106
Source: PubMed


Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point. Results of these phase II studies are typically compared with the phase III European Organization for Research and Treatment of Cancer (EORTC) survival data that resulted in RT + TMZ becoming standard therapy.
The New Approaches to Brain Tumor Therapy (NABTT) Consortium assigned 365 patients with glioblastoma to four single-cohort studies with similar eligibility criteria. Patients received RT + TMZ with talampanel (n = 72), poly-ICLC (n = 97), or cilengitide (n = 112) or RT + TMZ alone with monitoring of CD4 counts (n = 84). Overall survival of those ages 18 to 70 years with glioblastoma was compared with published EORTC data.
NABTT and EORTC patients had comparable performance status and debulking surgery. Median, 12-month, and 24-month survival rates for the EORTC patients (n = 287) and the comparable NABTT patients receiving RT + TMZ and novel agents (n = 244) are 14.6 versus 19.6 months, 61% versus 81%, and 27% versus 37%, respectively. This represents a 37% reduction in odds of death (P < 0.0001) through 2 years of follow-up. NABTT and EORTC patients receiving only RT + TMZ had similar survival.
Newly diagnosed glioblastoma treated recently with RT + TMZ and talampanel, poly-ICLC, or cilengitide had significantly longer survival than similar patients treated with only RT + TMZ accrued internationally from 2000 to 2002. These differences could result from the novel agents or changing patterns of care. Until the reasons for these different survival rates are clarified, comparisons of outcomes from phase II studies with published RT + TMZ survival data should be interpreted with caution.

37 Reads
  • Source
    • "Glioblastoma (GBM) is the most frequently diagnosed primary malignant brain tumor in adults (Dolecek et al., 2012). Standard therapy of surgical resection followed by temozolomide and radiation extends survival by only months (Grossman et al., 2010). Individual cells migrate up to several centimeters from the primary tumor (Giese et al., 1996) and compromise essential central nervous system (CNS) function (Batchelor, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma's (GBM) extensive invasive capacity makes it resistant to surgery, radio- and chemotherapy, and thus makes it lethal. In vivo, GBM invasion is mediated by Rho GTPases through unidentified downstream effectors. mammalian Diaphanous (mDia) family formins are Rho-directed effectors that regulate the F-actin cytoskeleton to support tumor cell motility. Historically, anti-invasion strategies focused upon mDia inhibition, while activation remained unexplored. The recent development of small molecules directly inhibiting or activating mDia-driven F-actin assembly that supports motility allows for exploration of their role in GBM. We used the formin inhibitor SMIFH2 and mDia agonists IMM-01/-02 and mDia2-DAD peptides which disrupt autoinhibition to examine the roles of mDia inactivation verses activation in GBM cell migration and invasion in vitro, and in an ex vivo brain slice invasion model. Inhibiting mDia suppressed directional migration and spheroid invasion, while preserving intrinsic random migration. mDia agonism abrogated both random intrinsic and directional migration and halted U87 spheroid invasion in ex vivo brain slices. Thus, mDia agonism is a superior GBM anti-invasion strategy. We conclude that formin agonism impedes the most dangerous GBM component, tumor spread into surrounding healthy tissue. Formin activation impairs novel aspects of transformed cells and informs the development of anti-GBM invasion strategies.
    Molecular biology of the cell 09/2015; DOI:10.1091/mbc.E14-11-1502 · 4.47 Impact Factor
  • Source
    • "A major advantage for using MSC as cytokine delivery vehicles is the ability of MSCs to selectively migrate to the tumor site and release the intended agent [93]. In addition to MSCs selectively homing to solid tumors they also actively home to sites of metastases, distant from the primary tumor [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The blood brain barrier (BBB) poses a problem to deliver drugs for brain malignancies and neurodegenerative disorders. Stem cells such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs) can be used to delivery drugs or RNA to the brain. This use of methods to bypass the hurdles of delivering drugs across the BBB is particularly important for diseases with poor prognosis such as glioblastoma multiforme (GBM). Stem cell treatment to deliver drugs to neural tumors is currently in clinical trial. This method, albeit in the early phase, could be an advantage because stem cells can cross the BBB into the brain. MSCs are particularly interesting because to date, the experimental and clinical evidence showed 'no alarm signal' with regards to safety. Additionally, MSCs do not form tumors as other more primitive stem cells such as embryonic stem cells. More importantly, MSCs showed pathotropism by migrating to sites of tissue insult. Due to the ability of MSCs to be transplanted across allogeneic barrier, drug-engineered MSCs can be available as off-the-shelf cells for rapid transplantation. This review discusses the advantages and disadvantages of stem cells to deliver prodrugs, genes and RNA to treat neural disorders.
    Clinical and Translational Medicine 07/2014; 3:24. DOI:10.1186/2001-1326-3-24
  • Source
    • "Glioma represents the majority of primary malignant brain tumors with low survival rate [1]. Despite advance in surgery, radiotherapy, and chemotherapy, over 50% of patients die within one year by diagnosis of glioblastoma [2]. Thus, it is very urgent to explore the mechanisms that underlie the occurrence and development of glioma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: To investigate the role and mechanism of miR-15b in the proliferation and apoptosis of glioma. Methods: The miR-15b mimics were transfected into human glioma cells to upregulate the miR-15b expression. Cyclin D1 was determined by both western blotting analysis and luciferase reporter assay. Methylthiazol tetrazolium (MTT) and flow cytometry were employed to detect the cell proliferation, cell cycle, and apoptosis. Results: Overexpression of miR-15b inhibits proliferation by arrested cell cycle progression and induces apoptosis, possibly by directly targeting Cyclin D1. Both luciferase assay and bioinformatics search revealed a putative target site of miR-15b binding to the 3'-UTR of Cyclin D1. Moreover, expression of miR-15b in glioma tissues was found to be inversely correlated with Cyclin D1 expression. Enforced Cyclin D1 could abrogate the miR-15b-mediated cell cycle arrest and apoptosis. Conclusions: Our findings identified that miR-15b may function as a glioma suppressor by targeting the Cyclin D1, which may provide a novel therapeutic strategy for treatment of glioma.
    BioMed Research International 06/2014; 2014:687826. DOI:10.1155/2014/687826 · 2.71 Impact Factor
Show more


37 Reads
Available from